Episode Details
Back to Episodes
In the News: Sernova transplant update, at-home T1D test moves forward, best diet for T2D, Mattel releases type 1 barbie and more!
Description
It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: Sernova has a new partner and a new drug for cell transplants, at home glucose/T1D test research, study looks at best diet for people with type 2, Lifescan files for banktrupcy, T1D Barbie and more!
Find out more about Moms' Night Out
Read Hangy Woman's take on Barbie (and send me yours!)
Please visit our Sponsors & Partners - they help make the show possible!
Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com)
Check out VIVI Cap to protect your insulin from extreme temperatures
The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:
Sign up for our newsletter here
Here's where to find us:
Learn more about everything at our home page www.diabetes-connections.com
Reach out with questions or comments: info@diabetes-connections.com
Episode transcription with links:
In the News
July 18
Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now.
XX
Sernova is partnering with Eledon Pharmaceuticals to test a new immunosuppressive drug in its ongoing clinical trial for people with type 1 diabetes (T1D). The drug called tegoprubart is designed to protect transplanted islet cells without harsh side effects. The current treatment is known for its potential toxicity, especially towards insulin-producing beta cells, and its adverse side effects, making it less than ideal for islet cell therapy in T1D.
Tegoprubart has already shown promise in earlier trials, helping T1D patients achieve insulin independence with better graft survival and fewer side effects.
This next phase of Sernova's trial (Cohort C) will combine Eledon's drug with Sernova's Cell Pouch, an implantable device that houses insulin-producing cells. In earlier phases, six participants stopped needing insulin completely, with results lasting years.
Sernova also plans to use stem cell-derived islet-like clusters from partner Evotec to create a next-gen therapy. If all goes well, a new clinical program could launch in